3.0
Jan 7, 2015
Anonymous employee
Former employee
Recommend
CEO approval
Business Outlook
Pros
Diversity in Oncology portfolio, very strong in oncology.
Cons
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.